Opinion
Video
Ronald D. Alvarez, MD, MBA, gives an analysis of the MIRASOL and DESTINY-PanTumor02 trials, including a comparison of study arms and discussion of HER2/neu targeting.
Immunotherapy for Angiosarcoma: Promising Results for Scalp and Face Tumors
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
Hemophilia A Gene Therapy Superior to Standard of Care in Phase 3 Trial
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
Dr Diane Mahoney on Tackling Ovarian Cancer Care Disparities
Atezolizumab for NSCLC Safe and Effective Before and After CRT